Table 3.
Risk of Disease Progression by C868T Polymorphism
| Genetic model | Genotype | Events/total (%)a | HR (95% CI) |
|---|---|---|---|
| CD4 decline below 200 by C868T polymorphism | |||
| Unadjusted | C/C | 35/301 (12%) | Reference |
| C/T or T/T | 8/101 (8%) | 0.69 (0.32, 1.49) p=0.35 | |
| Adjustedb | C/C | 34/255 (13%) | Reference |
| C/T or T/T | 7/92 (8%) | 0.45 (0.20, 1.02) p=0.06 | |
| CD4 decline below 200 or death by C868T polymorphism | |||
| Unadjusted | C/C | 38/301 (13%) | Reference |
| C/T or T/T | 10/101 (10%) | 0.80 (0.40, 1.60) p=0.53 | |
| Adjustedb | C/C | 35/255 (14%) | Reference |
| C/T or T/T | 8/92 (9%) | 0.50 (0.23, 1.09) p=0.08 | |
| CD4 decline below 350 by C868T polymorphism | |||
| Unadjusted | C/C | 68/259 (26%) | Reference |
| C/T or T/T | 22/84 (26%) | 1.10 (0.68, 1.78) p=0.70 | |
| Adjustedb | C/C | 60/217 (28%) | Reference |
| C/T or T/T | 21/77 (27%) | 0.82 (0.50, 1.35) p=0.43 | |
| CD4 decline below 350 or death by C868T polymorphism | |||
| Unadjusted | C/C | 71/259 (27%) | Reference |
| C/T or T/T | 22/84 (26%) | 1.05 (0.65, 1.70) p=0.83 | |
| Adjustedb | C/C | 61/217 (28%) | Reference |
| C/T or T/T | 21/77 (27%) | 0.80 (0.49, 1.32) p=0.39 | |
a
Cumulative event rate by 2 years.
b
Adjusted for baseline CD4 count.
HR, hazard ratio; CI, confidence interval.